Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023.

Revenue
−52.3%
EPS
+75.0%
Free cash flow
−38.7%

Quarter to June 2026, against a year earlier

1.34 0.06 −4.29%
Market cap
$84.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.76
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Piotroski F-Score
— 3 — — — — — — —
P/E ratio
— 0.00 0.00 0.00 — — — — —
Altman Z-Score
— (6.76) (4.32) (4.34) — — — — —
P/S ratio
— 0.65 0.70 0.00 — — — — —
P/FCF ratio
— 0.00 0.00 0.00 — — — — —
Altman Z″-Score (non-manufacturers)
— (19.02) (10.24) (8.03) — — — — —
Beneish M-Score
— — (0.88) — — — — — —
P/Operating CF
— (8.04) (4.48) 1.29 — — — — —
P/B ratio
— 1.39 1.12 1.12 — — — — —
EV/Sales
— 0.28 (0.22) 0.00 — — — — —
EV/EBITDA
— 0.00 0.53 0.34 — — — — —
EV/FCF
— (0.60) 0.36 2.92 — — — — —
Current Ratio
10.58 3.93 1.79 2.40 9.35 11.76 14.28 33.09 12.57
Net Debt/EBITDA
1.29 2.54 2.70 1.01 1.90 2.48 1.61 7.66 (0.56)
Debt/Equity
0.00 0.00 0.00 0.28 0.15 0.14 0.23 0.00 (3.58)
ROE
(93.99%) (38.75%) (48.92%) (126.83%) (57.28%) (53.38%) (47.95%) (42.28%) (7.22%)
ROA
(77.92%) (21.19%) (20.68%) (76.21%) (45.72%) (42.30%) (41.73%) (35.66%) (6.09%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(79.23%) (42.72%) (60.36%) (138.46%) (52.28%) (38.14%) (49.57%) (20.34%) (34.36%)
Average Days of Receivables
— 0.00 37.78 65.73 — — — — —
Earnings Yield
— (30.69%) (53.42%) (179.25%) — — — — —
Free Cash Flow Yield
— (72.07%) (86.13%) (25.21%) — — — — —
Free Cash Flow per Share
(0.40) (0.54) (0.63) (0.27) (1.12) (1.22) (1.32) (0.62) (0.07)
Book value per Share
0.50 0.54 0.65 0.95 2.31 3.43 2.41 5.33 (0.22)
Free Cash Flow
(22.78) (19.11) (21.83) (9.01) (32.14) (24.83) (23.02) (7.56) (0.66)
EV/EBIT
— 0.00 0.55 0.42 — — — — —
Other line items

Show all line items

Columns are period end dates